Wendy's rejects Trian's $1.4 billion buyout and adopts a poison pill as U.S. sales fall 7.6%

Wendy's said Thursday that its board has rejected a $1.4 billion offer to take the company private from a group led by Nelson Peltz's Trian Fund Management. CNBC reported that the group offered $7.35 a share in cash on October 28. The board's independent committee concluded the proposal "substantially undervalues" the company and ignores the gains it expects from its turnaround.

The board also adopted a one-year shareholder rights plan, known as a poison pill. According to Wendy's Form 8-K on SEC EDGAR, the plan imposes heavy dilution on any person or group that acquires 15% or more of the shares without board approval, counting economic exposure through derivatives. The filing says the investor group turned down a standstill agreement the company had offered first.

The number behind the number

The offer is below where the stock closed. Nasdaq data shows Wendy's finished Wednesday at $7.65, up 5.2% on the day, so $7.35 is about 4% under that close and roughly 27% under the 52-week high of $10.12. The group says it would acquire all shares it does not already own. The $1.4 billion figure is CNBC's, and Nasdaq lists the market value near $1.45 billion at Wednesday's close. The stock traded near $7.65 in pre-market on Thursday at 8:26 AM ET, so investors are not pricing in a higher bid so far.

The bidders are not only financial investors. According to CNBC, the group includes Trian, BlueFive Capital, Sixth Street Partners and Flynn Group, described as one of Wendy's largest franchisees. The 8-K notes the vote to adopt the pill excluded the directors affiliated with Trian, which still has two people on the board.

What the quarter says about the "undervalued" argument

The earnings release, filed the same morning, is the board's evidence and also the bidders' case. From the company's own table for the quarter ended September 27:

U.S. systemwide sales fell 7.6%, and global sales fell 5.9%. Revenue of $547.0 million was down 0.5%, and adjusted earnings per share of $0.13 compared with $0.24 a year earlier. CNBC noted that earnings and revenue still beat Wall Street's expectations, and that this was the seventh straight quarter of falling same-store sales.

The company argues it has room to invest: about $413 million in cash and $174 million of free cash flow in the first nine months. It also says a revised, location-by-location breakfast plan "could unlock up to $200 million in restaurant-level EBITDA across the system," a figure that is management's estimate, not a reported result.

Who it hits

• Franchisees. Wendy's franchise royalties are a share of sales, so falling traffic cuts the company's income and the operator's at the same time. The company said its U.S. company-operated restaurant margin fell 140 basis points to 11.7%, citing lower traffic, labor and commodity inflation. A rough read of the table: U.S. sales per restaurant were about $486,000 for the quarter against about $502,000 a year ago, down roughly 3%. The decline is smaller than the 5.7% same-store drop because the weakest locations are closing. That is our arithmetic on quarter-end counts, not a company figure.
• Operators in trouble. The company signed a letter of intent to acquire up to 163 restaurants from Meritage Hospitality Group and its lenders, subject to a definitive agreement, higher offers and court approval. We covered Meritage's Chapter 11 filing in September. Wendy's is now planning to take some restaurants back and move others to what it calls well-capitalized operators.
• Landlords and local suppliers. Net U.S. closures of 258 restaurants in the first nine months mean vacant pads and lost orders for local vendors. See our piece on what the Meritage case means for vendors, repair crews and landlords.
• Independent restaurants nearby.

  605,380 independent restaurants are listed on CheckThisBiz, a directory of 7,704,724 independent US businesses, including 79,108 in CA, 54,058 in TX, 51,387 in NY. Chains and franchises are excluded from that count, so these are the owner-operated businesses that actually apply for funding.

  The chain's retreat from weaker locations changes the competition on those blocks.

What to watch

The pill's rights go to shareholders of record on November 16. The open questions are whether Trian and its partners raise the bid, go directly to shareholders, or stay put, and whether Wendy's can show traffic improving before they do. CNBC noted that Dine Brands, owner of Applebee's, also adopted a poison pill recently to block a takeover bid, so activist pressure on struggling restaurant chains is not limited to Wendy's.

Sources: Wendy's Form 8-K (rights plan); Wendy's third-quarter 2026 earnings release; CNBC; Nasdaq.com quote data read November 5, 2026. Some data may be delayed. This is market information, not investment advice.